5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation

Juan A Marchal1, Houria Boulaiz, Fernando Rodríguez-Serrano

  • 1Departamento de Ciencias de la Salud, Universidade de Jaén, Jaén, Spain.

Insights

New 5-fluorouracil (5-FU) derivatives show promise in treating rhabdomyosarcoma by enhancing differentiation. These compounds increase human leukocyte antigen (HLA) class I expression and microtubule stability, potentially improving patient outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Neoplastic cells often have impaired differentiation, making differentiation therapy a key strategy for cancer control.
  • Rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma, is challenging to treat with conventional cytotoxic methods.
  • Alpha-tubulin and human leukocyte antigen (HLA) class I expression changes during cancer development.

Purpose of the Study:

  • To investigate the effects of novel 5-fluorouracil (5-FU) derivatives on human RMS RD cell lines.
  • To analyze the expression patterns of alpha-tubulin and HLA class I proteins after treatment with these 5-FU derivatives.
  • To assess the potential of these derivatives as differentiation agents for RMS.

Main Methods:

  • Treatment of human RMS RD cell lines with three categories of 5-FU derivatives.
  • Cytotoxicity assays to evaluate cell viability.
  • Scanning and transmission electron microscopy for ultrastructural analysis.
  • Flow cytometry and immunocytochemical analyses for protein expression.
  • Analysis of alpha-tubulin and HLA class I expression patterns.

Main Results:

  • Compound 1-[[3-(3-Chloro-2-hydroxypropoxy)-1-methoxy]propoxy]propyl]-5-fluorouracil (2) significantly increased tubulin levels and promoted its cytoplasmic distribution.
  • Compounds N,N-bis[3-(5-fluorouracil-1-yl)-3-methoxypropanoyl]-alpha,alpha;-diamino-m-xylene (5) and compound 2 markedly increased HLA class I protein expression.
  • The 5-FU derivatives enhanced microtubule stability and tubulin network formation, correlating with increased cell differentiation.

Conclusions:

  • 5-FU derivatives can modulate key markers of differentiation in RMS cells.
  • Increased HLA class I expression and enhanced microtubule stability are associated with the differentiation-inducing effects of these compounds.
  • These findings suggest a potential therapeutic benefit of these 5-FU derivatives for improving rhabdomyosarcoma prognosis.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...